Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) and water filtration systems (Dual Stage Ultrafilter). The company is a smaller reporting company with a 1:20 reverse stock split effective March 11, 2011.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Product Revenue | $681,000 | $989,000 |
| Gross Margin | $199,000 (29.2%) | $389,000 (39.3%) |
| Net Loss | $(707,000) | $(528,000) |
| Loss Per Share (Basic/Diluted) | $(0.18) | $(0.25) |
| Cash and Equivalents (End of Period) | $2,247,000 | $564,000 |
| Short-Term Debt | $0 | $500,000 |
| Accumulated Deficit | $(92,615,000) | $(91,908,000) |
Cash Flow Summary (Q1 2011):
- Operating Activities: $(548,000) used
- Financing Activities: $2,550,000 provided (primarily from equity issuance)
- Net Increase in Cash: $2,007,000
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 31% to $681,000, driven primarily by a $337,000 reduction in revenue from the U.S. Naval Research contract. This was partially offset by increased sales of Dual Stage Ultrafilter (DSU) products and STERIS project revenue.
- Cost Reductions: Cost of goods sold decreased 20% to $482,000, largely due to lower costs associated with the Naval Research contract.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased 10% to $729,000 due to lower severance and personnel costs, though this was offset by a $103,000 increase in stock-based compensation.
- Capital Structure: The company completed a rights offering and private placement in March 2011, raising approximately $3.2 million in gross proceeds. These funds were used to repay a $500,000 senior secured note to Lambda Investors LLC and cover transaction costs.
- Stock Split: A 1:20 reverse stock split was implemented on March 11, 2011, reducing outstanding shares from approximately 201.3 million to 10.1 million.
Outlook, Risks, and Management Commentary
- Going Concern: Management states that recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern. Current cash reserves are estimated to sustain operations only into the second quarter of 2012.
- Regulatory Status: The FDA denied a previous 510(k) submission for the company's HDF system. Management anticipates submitting a new application in Q3 2011. Conversely, the company received approval from Health Canada on May 10, 2011, to market its DSU water filtration system in Canada.
- Future Funding: The company expects to incur additional losses and will require additional financing to fund operations, R&D, and marketing. There is no assurance that such capital can be raised on satisfactory terms.
- Customer Concentration: Two customers (Customer A and B) accounted for 76% of sales in Q1 2011 and 88% of accounts receivable as of March 31, 2011.
- Supply Chain: The company's exclusive fiber supplier terminated its agreement in July 2010, though negotiations for a new agreement are ongoing.
Investor Verification Checklist
- Liquidity Runway: Verify the accuracy of management's estimate that cash reserves will last only until Q2 2012.
- Regulatory Approval: Monitor the status of the new 510(k) submission for the HDF system expected in Q3 2011.
- Revenue Concentration: Assess the risk associated with reliance on two major customers for the majority of sales and receivables.
- Capital Raising: Evaluate the company's ability to secure additional equity or debt financing given the "going concern" warning.
- Supply Agreement: Confirm the status of negotiations with the fiber supplier following the termination of the previous exclusive agreement.